核心观点:随着2024年海外市场逐渐回暖,部分国内CXO企业24年新签订单端展现良好增长趋势,25H1整体海外需求仍旧较好,25年有望逐渐在业绩上开始体现;国内投融资整体处于底部,恢复预计仍需要一定时间。细分来看,临床前及临床CRO行业24H2价格底部企稳,25年部分细分领域需求有所增加。CDMO早期项目价格战有所趋缓,海外业务增长强于国内。CXO行业25Q1整体开始恢复增长,但部分企业受24年...
Source Link核心观点:随着2024年海外市场逐渐回暖,部分国内CXO企业24年新签订单端展现良好增长趋势,25H1整体海外需求仍旧较好,25年有望逐渐在业绩上开始体现;国内投融资整体处于底部,恢复预计仍需要一定时间。细分来看,临床前及临床CRO行业24H2价格底部企稳,25年部分细分领域需求有所增加。CDMO早期项目价格战有所趋缓,海外业务增长强于国内。CXO行业25Q1整体开始恢复增长,但部分企业受24年...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.